Predictive Factors and Consequences of Myocardial Fibrosis in Hypertrophic Cardiomyopathy

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Fibrosis, myocardial deformation and biomarkers in hypertrophic cardiomyopathy (HCM)

Eligibility
Participation Requirements
Sex: All
Minimum Age: 16
Healthy Volunteers: No
View:

• Patients with known HCM or recently discovered with a wall thickness greater than or equal to15 mm without family background or> 13 mm in an HCM family context in the absence of other causes found capable of producing such a degree of hypertrophy

• HCM apparently linked to a mutation of a protein of the sarcomere (identified mutation or absence of other causes of hypertrophy found when the mutation search was not performed or was unsuccessful)

• Control subjects will be patients greater than or equal to 18 years without known cardiovascular disease or that may affect their ability to function, addressed to achieve a stress echocardiography for assessment of atypical symptoms, with a low pretest probability of coronary artery disease, and accepting blood sample before and after exercise. They do not realize Holter ECG or cardiac MRI as part of the study.

Locations
Other Locations
France
Nantes University Hospital
Recruiting
Nantes
Contact Information
Primary
Thierry Le Tourneau, PU-PH
thletourneau@yahoo.fr
0617908670
Time Frame
Start Date: June 2014
Estimated Completion Date: December 2021
Participants
Target number of participants: 115
Treatments
patients with obstructive HCM
patients with HCM (obstructive or no obstructive)
controls
patients without HCM
patients with non obstructive HCM
patients with non obstructive HCM
Sponsors
Leads: Nantes University Hospital
Collaborators: Rennes University Hospital, Institut National de la Santé Et de la Recherche Médicale, France, University Hospital, Lille

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

We couldn't find any related articles check for more on the main search page.